Healthcare
ByHow Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market share via Mounjaro/Zepbound ($39.5B 2025 revenue)…
How Does Bristol Myers Squibb Secure Multi-Billion Dollar Growth Through 8 Key Oncology Catalysts by 2030?
Bristol Myers Squibb strategically positions for next-decade dominance through its deep pipeline featuring 5 multi-billion-dollar assets (pumitamig, iberdomide, mezigdomide, milvexian, Cobenfy) across…
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030?
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030? Gilead Sciences executes a precision oncology…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
Can a Single Injection Change Everything? Novartis’s Itvisma Wins EU Approval for Broader SMA Population
Key Highlights Closing a Long-Standing Treatment Gap Itvisma’s approval extends gene replacement therapy to an SMA population that…
Can Novartis’s Up to $1.5 Billion Acquisition of Myricx Bio Unlock a New Generation of Cancer-Fighting Antibody-Drug Conjugates?
Key Highlights A Landmark Exit for Early-Stage Science Brandon Capital’s exit from Myricx Bio represents one of its…
